Loading...

MannKind

DB:NNFN
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NNFN
DB
$287M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • MannKind has significant price volatility in the past 3 months.
NNFN Share Price and Events
7 Day Returns
-2.3%
DB:NNFN
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-7.8%
DB:NNFN
-5.6%
DE Biotechs
-4.5%
DE Market
NNFN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MannKind (NNFN) -2.3% -21.7% 23.5% -7.8% -78.7% -94.2%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • NNFN underperformed the Biotechs industry which returned -5.6% over the past year.
  • NNFN underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
NNFN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is MannKind undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MannKind to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MannKind.

DB:NNFN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NNFN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (35.67%))
1.578
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.58
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.578 * 5.96%)
9.63%

Discounted Cash Flow Calculation for DB:NNFN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MannKind is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NNFN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.63%)
2019 -21.55 Analyst x1 -19.65
2020 -16.00 Analyst x1 -13.31
2021 -23.25 Analyst x1 -17.65
2022 -19.76 Analyst x1 -13.68
2023 13.00 Analyst x1 8.21
2024 17.59 Est @ 35.28% 10.13
2025 21.95 Est @ 24.77% 11.53
2026 25.77 Est @ 17.4% 12.35
2027 28.93 Est @ 12.25% 12.64
2028 31.43 Est @ 8.64% 12.53
Present value of next 10 years cash flows $3.11
DB:NNFN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $31.43 × (1 + 0.23%) ÷ (9.63% – 0.23%)
$334.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $334.96 ÷ (1 + 9.63%)10
$133.55
DB:NNFN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3.11 + $133.55
$136.65
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $136.65 / 187.77
$0.73
DB:NNFN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NNFN represents 0.87974x of NasdaqGM:MNKD
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87974x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.73 x 0.87974
€0.64
Value per share (EUR) From above. €0.64
Current discount Discount to share price of €1.35
= -1 x (€1.35 - €0.64) / €0.64
-110.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of MannKind is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MannKind's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MannKind's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NNFN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.60
NasdaqGM:MNKD Share Price ** NasdaqGM (2019-04-25) in USD $1.53
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MannKind.

DB:NNFN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MNKD Share Price ÷ EPS (both in USD)

= 1.53 ÷ -0.60

-2.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MannKind is loss making, we can't compare its value to the Europe Biotechs industry average.
  • MannKind is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MannKind's expected growth come at a high price?
Raw Data
DB:NNFN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
60.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MannKind, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MannKind's assets?
Raw Data
DB:NNFN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.94
NasdaqGM:MNKD Share Price * NasdaqGM (2019-04-25) in USD $1.53
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:NNFN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MNKD Share Price ÷ Book Value per Share (both in USD)

= 1.53 ÷ -0.94

-1.63x

* Primary Listing of MannKind.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MannKind has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess MannKind's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MannKind has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MannKind expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MannKind expected to grow at an attractive rate?
  • MannKind's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • MannKind's earnings growth is expected to exceed the Germany market average.
  • MannKind's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NNFN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NNFN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 60.8%
DB:NNFN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 29.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NNFN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NNFN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 253 15 62 2
2022-12-31 195 -30 19 2
2021-12-31 148 -46 -17 3
2020-12-31 111 -47 -35 3
2019-12-31 97 -42 -36 3
DB:NNFN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 28 -38 -87
2018-09-30 16 -93 -110
2018-06-30 13 -102 -119
2018-03-31 12 -95 -131
2017-12-31 11 -65 -117
2017-09-30 20 -48 -31
2017-06-30 180 -47 129
2017-03-31 178 -39 134
2016-12-31 175 -78 126
2016-09-30 162 -88 -205
2016-06-30 -85 -364
2016-03-31 -91 -363

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MannKind's earnings are expected to grow significantly at over 20% yearly.
  • MannKind's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NNFN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from MannKind Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NNFN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.29 0.45 0.13 2.00
2022-12-31 0.09 0.26 -0.08 2.00
2021-12-31 -0.07 0.14 -0.20 3.00
2020-12-31 -0.16 -0.09 -0.23 3.00
2019-12-31 -0.19 -0.07 -0.27 3.00
DB:NNFN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.60
2018-09-30 -0.83
2018-06-30 -0.98
2018-03-31 -1.19
2017-12-31 -1.13
2017-09-30 -0.31
2017-06-30 1.33
2017-03-31 1.42
2016-12-31 1.37
2016-09-30 -2.30
2016-06-30 -4.26
2016-03-31 -4.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MannKind will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MannKind's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MannKind has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MannKind performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MannKind's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MannKind does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare MannKind's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MannKind's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MannKind's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MannKind Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NNFN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 27.86 -86.98 79.72 8.74
2018-09-30 15.76 -110.01 85.02 11.16
2018-06-30 13.33 -118.73 83.35 13.48
2018-03-31 11.60 -131.39 80.19 13.63
2017-12-31 11.15 -117.33 74.96 14.12
2017-09-30 19.62 -30.58 67.01 12.17
2017-06-30 179.93 128.83 62.42 11.73
2017-03-31 177.77 134.21 54.97 18.05
2016-12-31 174.76 125.66 46.93 14.92
2016-09-30 162.35 -205.33 37.81 20.28
2016-06-30 -363.71 35.02 20.70
2016-03-31 -362.66 34.53 19.00
2015-12-31 -368.45 40.96 29.67
2015-09-30 -127.87 43.99 39.02
2015-06-30 -132.53 52.73 53.85
2015-03-31 -176.98 74.63 83.44
2014-12-31 -198.38 79.38 100.24
2014-09-30 -215.52 84.47 111.67
2014-06-30 -229.82 82.86 119.78
2014-03-31 -202.58 64.87 109.50
2013-12-31 -191.49 59.68 109.72
2013-09-30 0.00 -189.69 52.41 106.01
2013-06-30 0.04 -181.70 44.10 104.18
2013-03-31 0.04 -172.16 39.24 103.76
2012-12-31 0.04 -169.37 45.47 101.52
2012-09-30 0.04 -153.98 37.35 91.79
2012-06-30 0.00 -149.55 37.82 81.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MannKind has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if MannKind has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MannKind improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MannKind's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MannKind has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MannKind's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MannKind's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MannKind is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MannKind's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MannKind's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • MannKind has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MannKind Company Filings, last reported 3 months ago.

DB:NNFN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -175.08 102.49 71.16
2018-09-30 -205.44 105.48 10.45
2018-06-30 -206.62 129.36 26.18
2018-03-31 -223.21 140.27 26.71
2017-12-31 -214.73 156.82 43.95
2017-09-30 -251.02 165.27 20.09
2017-06-30 -221.24 164.80 43.38
2017-03-31 -198.73 148.96 47.98
2016-12-31 -183.59 148.50 22.90
2016-09-30 -238.69 219.25 35.53
2016-06-30 -366.58 222.57 63.73
2016-03-31 -373.46 220.98 27.65
2015-12-31 -350.33 214.09 59.07
2015-09-30 -124.57 194.94 32.93
2015-06-30 -115.48 251.53 107.19
2015-03-31 -97.03 222.48 120.84
2014-12-31 -73.77 224.91 120.84
2014-09-30 -40.68 221.27 172.47
2014-06-30 -46.38 186.15 41.21
2014-03-31 17.54 174.05 35.76
2013-12-31 -30.71 250.26 70.79
2013-09-30 -167.72 405.69 93.80
2013-06-30 -152.36 332.38 28.53
2013-03-31 -146.81 332.02 28.01
2012-12-31 -110.68 331.66 61.84
2012-09-30 -276.25 434.82 1.77
2012-06-30 -244.38 429.33 31.99
  • MannKind has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if MannKind's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MannKind has sufficient cash runway for 1.9 years based on current free cash flow.
  • MannKind has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -4.5% each year.
X
Financial health checks
We assess MannKind's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MannKind has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MannKind's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MannKind dividends.
If you bought €2,000 of MannKind shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MannKind's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MannKind's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NNFN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NNFN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MannKind has not reported any payouts.
  • Unable to verify if MannKind's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MannKind's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MannKind has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MannKind's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MannKind afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MannKind has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MannKind's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Castagna
COMPENSATION $1,508,741
AGE 41
TENURE AS CEO 1.9 years
CEO Bio

Dr. Michael E. Castagna, Pharm.D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016 until July 12, 2017 and served as its Corporate Vice President since March 2016. Dr. Castagna leads commercialization efforts for Afrezza. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna has been Director of MannKind Corporation since May 25, 2017. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington. Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy and his MBA from the Wharton School of Business at the University of Pennsylvania.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MannKind management team in years:

1.8
Average Tenure
52
Average Age
  • The average tenure for the MannKind management team is less than 2 years, this suggests a new team.
Management Team

Michael Castagna

TITLE
CEO & Director
COMPENSATION
$2M
AGE
41
TENURE
1.9 yrs

Steven Binder

TITLE
Chief Financial Officer
COMPENSATION
$854K
AGE
55
TENURE
1.8 yrs

David Thomson

TITLE
Executive VP
COMPENSATION
$915K
AGE
51
TENURE
17.3 yrs

Pat McCauley

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
52
TENURE
1.8 yrs

David Kendall

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
56
TENURE
1.2 yrs

Joseph Kocinsky

TITLE
Chief Technology Officer
COMPENSATION
$708K
AGE
54
TENURE
3.5 yrs

Rose Alinaya

TITLE
Senior VP of Investor Relations & Treasury
COMPENSATION
$520K
AGE
57

Courtney Barton

TITLE
VP and Chief Compliance & Privacy Officer
AGE
35
TENURE
1.7 yrs

Elizabeth Ingram

TITLE
Chief Marketing Officer
AGE
52

Stuart Tross

TITLE
Chief People & Workplace Officer
COMPENSATION
$1M
AGE
51
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the MannKind board of directors in years:

14.5
Average Tenure
74
Average Age
  • The average tenure for the MannKind board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Kent Kresa

TITLE
Chairman
COMPENSATION
$232K
AGE
80
TENURE
3.2 yrs

Michael Castagna

TITLE
CEO & Director
COMPENSATION
$2M
AGE
41
TENURE
1.9 yrs

Ronald Consiglio

TITLE
Director
COMPENSATION
$205K
AGE
74
TENURE
15.5 yrs

Michael Friedman

TITLE
Director
COMPENSATION
$192K
AGE
74
TENURE
15.3 yrs

Jay Skyler

TITLE
Member of Scientific Advisory Board
AGE
71

David MacCallum

TITLE
Director
COMPENSATION
$185K
AGE
80
TENURE
14.8 yrs

Hank Nordhoff

TITLE
Director
COMPENSATION
$185K
AGE
76
TENURE
14.1 yrs

Julio Rosenstock

TITLE
Member of Scientific Advisory Board

Daniel Porte

TITLE
Member of Scientific Advisory Board

Geremia Bolli

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MannKind insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Mar 19 Buy Michael Castagna Individual 14. Nov 18 14. Nov 18 25,000 €1.56 €39,099
13. Mar 19 Buy Stuart Tross Individual 14. Nov 18 14. Nov 18 14,124 €1.56 €22,090
13. Mar 19 Buy David Kendall Individual 14. Nov 18 14. Nov 18 2,824 €1.56 €4,417
13. Mar 19 Buy James McCauley Individual 14. Nov 18 14. Nov 18 14,124 €1.56 €22,090
31. Jan 19 Buy Stuart Tross Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
31. Jan 19 Buy Steven Binder Individual 31. Jan 19 31. Jan 19 1,860 €0.93 €1,737
31. Jan 19 Buy James McCauley Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
31. Jan 19 Buy David Kendall Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
31. Jan 19 Buy Elizabeth Ingram Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
31. Jan 19 Buy Courtney Barton Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
31. Jan 19 Buy Michael Castagna Individual 31. Jan 19 31. Jan 19 5,000 €0.93 €4,671
06. Aug 18 Buy Stuart Tross Individual 02. Aug 18 02. Aug 18 5,000 €1.13 €5,640
06. Aug 18 Buy Michael Castagna Individual 02. Aug 18 02. Aug 18 5,000 €1.13 €5,640
06. Aug 18 Buy James McCauley Individual 02. Aug 18 02. Aug 18 5,000 €1.13 €5,640
06. Aug 18 Buy Courtney Barton Individual 02. Aug 18 02. Aug 18 5,000 €1.13 €5,640
06. Aug 18 Buy Steven Binder Individual 02. Aug 18 02. Aug 18 1,760 €1.13 €1,985
X
Management checks
We assess MannKind's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MannKind has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Details
Name: MannKind Corporation
NNFN
Exchange: DB
Founded: 1991
$256,697,426
187,774,030
Website: http://www.mannkindcorp.com
Address: MannKind Corporation
30930 Russell Ranch Road,
Suite 300,
Westlake Village,
California, 91362,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MNKD Common Stock Nasdaq Global Market US USD 28. Jul 2004
DB NNFN Common Stock Deutsche Boerse AG DE EUR 28. Jul 2004
Number of employees
Current staff
Staff numbers
225
MannKind employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:33
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/05
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.